Abstract
Recent studies have identified the mutational landscape of pancreatic cancer and suggested tumor‐specific subtypes. However, the major hurdle against personalized treatment is the difficulty to obtain sufficient cancer tissues from most inoperable cases. We investigated whether patient‐derived conditionally reprogrammed cells (CRCs) can be constructed using a small piece of tumor tissue using endoscopic ultrasound (EUS)‐guided fine needle biopsy (FNB). Thirty patients with pancreatic solid mass (mean size, 34.6 mm) were enrolled prospectively. Among 22 patients who were diagnosed with pancreatic ductal adenocarcinoma, we established patient‐derived pancreatic cancer cell lines from eight patients (36.4%). Immunofluorescence colony staining for CRCs showed that the cytoplasm of cancer cells was clearly stained with anti‐cytokeratin 19 monoclonal antibody. In the soft agar colony formation assay, CRCs formed colonies compared with the negative control by day 15. In vivo, implanted CRCs showed tumor engraftment and hematoxylin and eosin staining showed pancreatic cancer ductal structure. All established CRCs showed a KRAS mutation. In conclusion, we established patient‐derived pancreatic cancer cell lines with a small tumor tissue obtained by EUS‐FNB. With in vitro drug sensitivity and genomic studies, established patient‐derived cell lines can be used in identification of new targets for diagnosis and treatment of pancreatic cancer.
Highlights
Recent advances in cancer genomics have driven a paradigm change in anticancer treatment toward personalized therapy according to the genetic signature of each patient.[1,2] generation sequencing methods have identified genetic changes, including single nucleotide variants, and have allowed the classification of subtypes of pancreatic cancer according to their different treatment responses
We aimed to investigate whether patient‐derived preclinical cancer models can be constructed using a small piece of tumor tissue obtained via endoscopic ultrasound (EUS)‐fine needle biopsy (FNB) in pancreatic adenocarcinoma
We checked the KRAS mutation in conditionally reprogrammed cells (CRCs) to confirm whether the CRCs reflect the original characteristics of pancreatic ductal adenocarcinoma (PDAC)
Summary
Recent advances in cancer genomics have driven a paradigm change in anticancer treatment toward personalized therapy according to the genetic signature of each patient.[1,2] generation sequencing methods have identified genetic changes, including single nucleotide variants, and have allowed the classification of subtypes of pancreatic cancer according to their different treatment responses. To utilize these genetic features of pancreatic cancer, various recent preclinical models were introduced to pancreatic cancer research.[3] The successful application of preclinical cancer models derived from tumor tissue provides the opportunity for personalized drug selection and prognosis prediction. We aimed to investigate whether patient‐derived preclinical cancer models can be constructed using a small piece of tumor tissue obtained via EUS‐FNB in pancreatic adenocarcinoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
